Rucaparib

产品说明书

Print
Chemical Structure| 283173-50-2 同义名 : AG014699; PF-01367338; AG-014447
CAS号 : 283173-50-2
货号 : A115210
分子式 : C19H18FN3O
纯度 : 98%
分子量 : 323.36
MDL号 : MFCD11977252
存储条件:

Pure form Keep in dark place, sealed in dry, 2-8°C

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 25 mg/mL(77.31 mM),配合低频超声,并调节pH至4,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 PARP1, also called as Poly(ADP-ribose) polymerase, is involved in the signaling of DNA damage. It can recognize and bind DNA single or double-strand breaks, thus possessing various cellular function, including regulation of apoptosis and chromosome stability, gene amplification and transcription, as well as cell division and differentiation. Rucaparib is a potent PARP inhibitor with Ki value of 1.4nM (measured by enzyme assays). Rucaparib at dose ranging in 1-10μM can suppress the level of PAR, as well as induce γ-H2AX, formation and PARP cleavage in a dose-dependent manner indicative of DNA damage and apoptosis, respectively, in MDA-MB468, MDA-MB-231, and Cal-51 cells in the presence of 5% FBS-supplemented DMEM medium for 72h. Rucaparib at concentrations>2.5μM decreased the p-Stat3 in MDA-MB-468 and MDA-MB-231, as well as dose-dependently increased the p-Akt-S473 in MDA-MB-468 and Cal-51 cells. Rucaparib can chemosensitize neuroblastoma cell lines to temozolomide or topotecan in vitro and in vivo. Rucaparib at concentration of 0.4μM caused a significant sensitization of topotecan (1-30nM) and temozolomide (1-200μM) in NB-1691, SH-SY-5Y and SKNBE(2c) cells. Rucaparib (1mg/kg) increased the temozolomide-induced (68mg/kg) tumor growth delay by 50% (to >89 days) and complete and increased the number of mice with complete and persistent tumor regressions (‎≥100 days). Co-administration of Rucaparib (1mg/kg) with topotecan (1mg/kg) increased total number of complete regressions.
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.09mL

0.62mL

0.31mL

15.46mL

3.09mL

1.55mL

30.93mL

6.19mL

3.09mL

参考文献

[1]Daniel RA, Rozanska AL, et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res. 2009 Feb 15;15(4):1241-9.

[2]Thomas HD, Calabrese CR, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007 Mar;6(3):945-56.

[3]Kondrashova O, Topp M, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018 Sep 28;9(1):3970.

[4]Rucaparib